No Data
Osecon: Report for the third quarter of 2024
beijing aosaikang pharmaceutical (002755.SZ) net income in the third quarter increased by 296.25% year-on-year.
Galunhui October 30th | Beijing Aosaikang Pharmaceutical (002755.SZ) released its third quarter report, with the company achieving revenue of 1.384 billion yuan in the first three quarters, a year-on-year increase of 23.64%; net income of 0.127 billion yuan, a year-on-year increase of 168.79%. In the third quarter alone, revenue reached 0.462 billion yuan, up 13.23% year-on-year; net income was 51.4232 million yuan, up 296.25% year-on-year.
Hong Kong stocks anomaly | Innovent Bio (01801) fell another 10% during the day, reaching a strategic cooperation with Beijing Aosaikang Pharmaceutical, the founder recently reduced holdings by over 0.15 billion Hong Kong dollars of stocks
Innovent Bio (01801) fell by another 10% during the day, as of the time of publication, a decrease of 4.92%, closing at HKD 47.35, with a turnover of 1.627 billion Hong Kong dollars.
Innovent Bio and Beijing Aosaikang Pharmaceutical have reached a global strategy cooperation for the third generation EGFR TKI lung cancer targeted drug Elunate tablets (Aoyixin).
San Francisco, usa and Suzhou, china - October 8, 2024 / PRNewswire / - On September 30, 2024, Innovent Bio (Hong Kong Stock Exchange stock code: 01801), a biopharmaceutical company dedicated to researching, developing, producing and selling innovative drugs in major disease areas such as oncology, autoimmune, cardiovascular and metabolism, ophthalmology, etc., announced a cooperation agreement with Beijing Aosaikang Pharmaceutical (Shenzhen Stock Exchange stock code: 002755), to declare that the two parties have reached an exclusive business agreement on the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeted drug Iletisib tablets (Oselex).
Osecon: 2024 Semi-Annual Report
Osecon: 2024 Semi-Annual Report Summary
No Data
